[beta]-blockers may not be beneficial one year post MI. Two recent studies raise questions about the current practice of routinely prescribing [beta]-blockers in patients with heart failure and myocardial infarction (MI). The first, published online May 1 in JACC: Heart Failure, found that while use of [beta]-blockers lowered the risks of hospitalization and death in patients with reduced ejection fraction, it increased risk in patients with an ejection fraction equal to or greater than 40%, with particularly high risk in those with an ejection fraction above 60%, regardless of the presence of other cardiac-related morbidities such as hypertension or arrythmias. The second study, which was published online May 2 in Heart, examined the long-term use of [beta]-blockers post MI, a practice based on past studies that found [beta]-blockers lowered mortality rates in MI patients. However, as the researchers note, recent improvements in MI treatment mean fewer MI survivors are left with heart failure or left ventricular systolic dysfunction. The findings of this study indicate that there is no longer a benefit to the use of [beta]-blockers beyond the first year after an MI. Clinicians need to reconsider indications for [beta]-blockers in individual patients.